BriaCell Adds Penn Medicine’s Abramson Cancer Center to Phase 3 Breast Cancer Trial
BriaCell has added Penn Medicine’s Abramson Cancer Center as a clinical site in its pivotal Phase 3 Bria-ABC breast cancer study alongside sites at Indiana University, UVA, Baptist Health South Florida and SCRI Oncology Partners. The trial, evaluating Bria-IMT plus an immune checkpoint inhibitor versus physician’s choice, targets overall survival with an interim analysis after 144 patient deaths under FDA Fast Track designation.
1. Clinical Site Expansion
BriaCell has added Penn Medicine’s Abramson Cancer Center as a clinical trial site for the Bria-ABC study, expanding its footprint at a world-renowned cancer institute in Philadelphia. This follows recent activations at Indiana University, University of Virginia, Baptist Health South Florida and SCRI Oncology Partners.
2. Trial Design and Endpoints
The Bria-ABC pivotal Phase 3 study evaluates the Bria-IMT immunotherapy regimen combined with an immune checkpoint inhibitor versus physician’s choice of treatment in patients with advanced metastatic breast cancer. Overall survival is the primary endpoint, with an interim analysis planned after 144 patient deaths.
3. FDA Fast Track Designation
The Bria-IMT combination regimen holds FDA Fast Track status, reflecting its potential to address a serious unmet need in metastatic breast cancer and potentially expedite development and review timelines.
4. Enrollment Momentum and Future Outlook
BriaCell reports increased interest from leading cancer centers and continued enrollment momentum following independent inclusion of its study in a prominent medical journal’s list of trials shaping 2026. The company aims to drive further site additions and patient accrual ahead of the interim analysis.